대한신장학회

Skip Navigation: Skip to contents

KOR
ENG
전체메뉴보기

간행물 검색

현재 페이지 경로

HOME
간행물
간행물 검색

논문분류	춘계학술대회 초록집
제목	Renoprotective Effects of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Kidney Disease: A Systematic Review and Meta-Analysis
저자	Joseph Paulo Gonzales
출판정보	2026; 2026(1):
키워드	DPP4 inhibitors, Diabetic kidney disease, Renoprotection, Albuminuria
초록	Objectives: Albuminuria is the first clinically evident feature of renal involvement in diabetic kidney disease (DKD). Treatments aimed at reducing albuminuria slow the progression of DKD. The incretin effect, mediated by the glucagon-like peptide-1 (GLP-1), reduces renal inflammation, fibrosis, and albuminuria. Dipeptidyl peptidase-4 inhibitors (DPP4I) prevent degradation of GLP-1 and renal effects include reduction in albuminuria. Given the potential of DPP4I in delaying the DKD progression, there is a need to summarize and review the current evidence to guide management of DKD. This study aims to determine the efficacy of DPP4I in delaying the progression of DKD. Methods: A computerized literature search of MEDLINE, CENTRAL, and ClinicalTrials.gov was done from inception to October 2025. Outcomes of interest included change in urine albumin-to-creatinine ratio (UACR) and in estimated glomerular filtration rate (eGFR). The risk of bias of the included studies was independently assessed by two authors and disagreements were resolved by consensus. Results: Fourteen randomized controlled trials (RCTs) satisfied the inclusion criteria, thirteen of the RCTs enrolling 31,528 participants were included in the quantitative synthesis. The risk of bias of the studies was low to moderate. Meta-analysis showed significant reduction in UACR after treatment with DPP4I compared to control (7 RCTs, 20,689 participants, MD -11.06 mg/g Crea, 95% CI -21.37 to -0.75). There was no significant difference in change in eGFR between DPP4I and control. Conclusion: DPP4 inhibitors were found to significantly decrease UACR and may delay the progression of DKD.
원문(PDF)	PDF 원문보기

목록

위로가기